Ark Fund

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psychedelics biotech’s stocks plummeted. The closing stock price on Jan. 11 was $1.72, more than 90% below its IPO price from...

The four-day trading week saw no weakness in SPAC deal announcements or headlines, all of which we followed on Benzinga's SPACS Attack show. Here is a look back at the deals announced, some new SPACs to watch and top headlines. SPAC Deals: There were eight announced SPAC deals during the...